Free Trial

Anixa Biosciences 9/6/2024 Earnings Report

Anixa Biosciences logo
$2.84 -0.13 (-4.51%)
As of 03:53 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Anixa Biosciences EPS Results

Actual EPS
-$0.10
Consensus EPS
-$0.11
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

Anixa Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Anixa Biosciences Announcement Details

Quarter
Time
After Market Closes

Conference Call Resources

Remove Ads

Anixa Biosciences Earnings Headlines

Research Analysts Offer Predictions for ANIX Q1 Earnings
The Same Setup That Led to a 131% Gold Surge Is Happening Now
Historically, when confidence in credit markets gets too high, a gold acceleration phase follows… And we’re seeing the same setup playing out again… With central banks piling into gold, inflation lingering, and debt levels soaring, I believe we’re on the verge of another Gold acceleration cycle—and it could happen fast. Back in November, I told folks to “buy the dip” in gold and I sure hope they listened… I cannot promise future returns or against losses, but now I’m giving you another heads-up… I broke down exactly what I am seeing and how anyone with a regular brokerage account can take advantage… Without actually holding any gold…
See More Anixa Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Anixa Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Anixa Biosciences and other key companies, straight to your email.

About Anixa Biosciences

Anixa Biosciences (NASDAQ:ANIX), a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

View Anixa Biosciences Profile

More Earnings Resources from MarketBeat